Alkermes, Inc., a biotechnology company committed to developing innovative medicines to improve patients’ lives, manufactures RISPERDAL® CONSTA® for schizophrenia and developed and manufactures VIVITROL® for alcohol dependence. Alkermes’ robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research and manufacturing facilities in Massachusetts and Ohio.

Collaborative Agreements
To maximize the potential for products to make a difference in patients' lives, Alkermes has development and marketing agreements with some of the world's leading pharmaceutical companies:

• Amylin Pharmaceuticals, Inc.
• Cephalon, Inc.
• Janssen-Cilag, a wholly owned division of Johnson & Johnson
• Cilag GmbH International

Amylin Pharmaceuticals, Inc.

In collaboration with Amylin Pharmaceuticals, Inc., we have developed exenatide once weekly, a Medisorb® formulation of BYETTA® (exenatide) for the treatment of type 2 diabetes. This long-acting release formulation has the potential to provide important therapeutic benefits in a once-weekly dosing regimen.

• Alkermes is responsible for developing potential long-acting formulations of exenatide.
• Amylin is responsible for conducting clinical trials, securing regulatory approvals, manufacturing exenatide once weekly for commercial sale, and for the sales and marketing of any products resulting from the collaboration.
• Alkermes will receive royalty payments on net product sales.
• Amylin has entered a collaboration agreement with Eli Lilly and Company for the development and commercialization of exenatide, including certain rights to exenatide once weekly.

Cephalon, Inc.

Alkermes is collaborating with Cephalon, Inc. on the development and commercialization of VIVITROL® (naltrexone for extended-release injectable suspension) in the U.S.

• Alkermes is responsible for manufacturing and clinical development of VIVITROL.
• Cephalon has primary responsibility for the marketing and sale of VIVITROL in the U.S., and Alkermes augments this sales effort.

Janssen-Cilag

Alkermes is collaborating with Janssen-Cilag (Janssen), a division of Johnson & Johnson, to market RISPERDAL® CONSTA® [(risperidone) long-acting injection], a long-acting injection of the oral medicine RISPERDAL® (risperidone) for the treatment of schizophrenia. RISPERDAL CONSTA uses Alkermes’ Medisorb technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks.

• Janssen markets RISPERDAL CONSTA in over 60 countries worldwide, including the U.S. and major European markets.
• Alkermes is responsible for manufacturing RISPERDAL CONSTA.

Cilag GmbH International

We have an agreement with Cilag GmbH International, a subsidiary of Johnson & Johnson, to commercialize VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence in Russia and other countries in the Commonwealth of Independent States (CIS).

• Janssen-Cilag, an affiliate company of Cilag GmbH International, is responsible for securing all necessary regulatory approvals and will commercialize VIVITROL in Russia and other countries in the Commonwealth of Independent States (CIS).
• Alkermes is responsible for manufacturing VIVITROL and will receive manufacturing revenues and royalty revenues based on product sales.